Grace Therapeutics, Inc. Increase (Decrease) in Other Operating Assets
Grace Therapeutics, Inc. (GRCE) reported Increase (Decrease) in Other Operating Assets of -$25.00 thousand for the 12-month period ending 2021-03-31, per its 10-K filed 2021-06-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2021-06-22
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2020-12-31 was -$1.00K.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2020-09-30 was -$24.00K.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2020-06-30 was $0.00.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2021 was -$25.00K, a 111.11% decline from fiscal 2020.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2020 was $225.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-22 | -$1.00K derived: sum of 2 quarters · filed 2021-06-22 | -$25.00K derived: sum of 3 quarters · filed 2021-06-22 | -$25.00K 10-K · filed 2021-06-22 |
| 2020-12-31 | -$1.00K 10-Q · filed 2021-02-09 | -$25.00K derived: sum of 2 quarters · filed 2021-02-09 | -$25.00K 10-Q · filed 2021-02-09 | $200.00K derived: sum of 4 quarters · filed 2021-06-22 |
| 2020-09-30 | -$24.00K 10-Q · filed 2020-11-16 | -$24.00K 10-Q · filed 2020-11-16 | $201.00K derived: sum of 3 quarters · filed 2021-06-22 | $191.00K derived: sum of 4 quarters · filed 2021-06-22 |
| 2020-06-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2021-06-22 | $225.00K derived: sum of 2 quarters · filed 2021-06-22 | $215.00K derived: sum of 3 quarters · filed 2021-06-22 | |
| 2020-03-31 | $225.00K 10-K · filed 2020-06-29 | $215.00K derived: sum of 2 quarters · filed 2021-02-09 | $225.00K 10-K · filed 2021-06-22 | |
| 2019-12-31 | -$10.00K 10-Q · filed 2021-02-09 | -$10.00K 10-Q · filed 2021-02-09 | ||
| 2019-03-31 | -$28.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |